The cortisone market size is projected to be USD 3.36 billion in 2025, USD 3.58 billion in 2026, and reach USD 4.92 billion by 2031, growing at a CAGR of 6.55% from 2026 to 2031. This report is segmented by Product Type (Acetate, Sodium Phosphates, Others), Dosage Form (Oral, Injectable, Topical, Others), Route of Administration (Oral, Intra-Articular, Intramuscular, Others), Therapeutic Application (Adrenal Insufficiency, Rheumatoid Arthritis, Others), End User (Hospitals, Clinics, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Cortisone Sodium Phosphates are projected to grow at a CAGR of 9.23% from 2026 to 2031, the highest rate among product types. Water solubility supports intravenous administration in hospital, critical-care, and perioperative settings. Demand for ready-to-use formulations is increasing, particularly for adrenal crisis and severe anaphylaxis protocols. Suspension and compounded products retain smaller roles in dermatological and ophthalmic applications.
Injectable Preparations accounted for 54.34% of dosage-form revenue in 2025, representing the largest dosage-form segment in the cortisone market. They support intra-articular, intramuscular, and intravenous administration across rheumatology, orthopedics, emergency medicine, and critical care. Recurring hospital and specialty-clinic procurement arrangements help stabilize demand. Injectable products remain important when rapid treatment is required or oral administration is unsuitable.
Oral Tablets are projected to grow at a CAGR of 8.88% from 2026 to 2031, the fastest rate among dosage forms. Growth is driven by outpatient chronic-disease management, dose tapering, and replacement therapy for congenital adrenal hyperplasia and adrenal insufficiency. Modified-release products provide more tailored dosing, although availability varies by country. A 2025 study of 790 patients found that modern glucocorticoid therapies had reached only 5% of the observed congenital adrenal hyperplasia cohort by 2023. Immediate-release tablets remain important as affordable options for outpatient tapering schedules.
Asia-Pacific was forecast to grow at a CAGR of 11.65% through 2031, the fastest regional growth rate in the Cortisone market. China remained a major corticosteroid active pharmaceutical ingredient production base, while India combined export-oriented manufacturing with growing domestic demand. Japan, South Korea, Vietnam, Indonesia, and Thailand offered growth potential through aging populations, increasing healthcare access, and improving specialist density.
The Middle East and Africa remained constrained by affordability, although health infrastructure investment in Saudi Arabia and the United Arab Emirates improved access to essential corticosteroid treatment. Suppliers needed to balance cost-competitive offerings, reliable supply, regulatory compliance, product registrations, distribution capacity, and pricing across varied reimbursement systems. These conditions favored lower-cost generic products in some markets and differentiated formulations in others.
Global Cortisone Market Trends and Insights
Rising Burden of Osteoarthritis, Rheumatoid Arthritis and Gout
Joint and connective tissue disorders remained a key demand driver for the cortisone market. The CDC reported that 25.7 million of the 58.5 million US adults with arthritis experienced activity limitations due to the condition and projected that 34.6 million adults would have activity-limiting arthritis by 2040. Corticosteroids played a short-term role in controlling disease activity before disease-modifying therapies became fully effective. Acute gout also supported demand when colchicine or nonsteroidal anti-inflammatory drugs were unsuitable.Growth in Adrenal-Insufficiency Diagnosis and Replacement Therapy
Newborn screening and improved diagnostic practices expanded the treated population for congenital adrenal hyperplasia and adrenal insufficiency. Screening programs used 17-hydroxyprogesterone testing to identify infants with classic congenital adrenal hyperplasia at birth, creating a need for lifelong glucocorticoid replacement. The FDA approved crinecerfont in December 2024 as an adjunct treatment for classic congenital adrenal hyperplasia, to be used alongside glucocorticoid replacement. A 2025 review identified modified-release hydrocortisone and CRF1 antagonists as major developments that reduced steroid exposure while maintaining adrenal control.Adverse Effects Associated with Cumulative Glucocorticoid Exposure
Safety concerns related to prolonged glucocorticoid use limit cortisone use in chronic care. A 2024 clinical review reported that 30% of long-term users developed secondary osteoporosis, while 30% to 50% of patients receiving extended treatment experienced fractures. Glucocorticoid users also faced a 160% to 185% higher spinal-fracture risk than healthy non-users. European guidelines recommended bone-risk assessments and preventive treatment for patients receiving 7.5 mg per day or more, supporting a shift toward steroid-sparing therapies and reducing the potential for long-term repeat prescribing in the Cortisone market.Other drivers and restraints analyzed in the detailed report include:
- Preference for Rapid and Low-Cost Anti-Inflammatory Treatment
- Expansion of Outpatient Orthopedic and Sports-Medicine Procedures
- Competition, Price Erosion, and Supply Vulnerability
Segment Analysis
Cortisone Acetate accounted for 56.45% of product-type revenue in 2025, making it the primary revenue contributor in the cortisone market. Established oral protocols, broad generic formulary inclusion, and continued replacement use support demand. Generic competition has reduced acquisition costs, sustaining volumes despite pressure on manufacturer margins. Familiar dosing and broad availability reinforce its use in treatment pathways that prioritize reliable access.Cortisone Sodium Phosphates are projected to grow at a CAGR of 9.23% from 2026 to 2031, the highest rate among product types. Water solubility supports intravenous administration in hospital, critical-care, and perioperative settings. Demand for ready-to-use formulations is increasing, particularly for adrenal crisis and severe anaphylaxis protocols. Suspension and compounded products retain smaller roles in dermatological and ophthalmic applications.
Injectable Preparations accounted for 54.34% of dosage-form revenue in 2025, representing the largest dosage-form segment in the cortisone market. They support intra-articular, intramuscular, and intravenous administration across rheumatology, orthopedics, emergency medicine, and critical care. Recurring hospital and specialty-clinic procurement arrangements help stabilize demand. Injectable products remain important when rapid treatment is required or oral administration is unsuitable.
Oral Tablets are projected to grow at a CAGR of 8.88% from 2026 to 2031, the fastest rate among dosage forms. Growth is driven by outpatient chronic-disease management, dose tapering, and replacement therapy for congenital adrenal hyperplasia and adrenal insufficiency. Modified-release products provide more tailored dosing, although availability varies by country. A 2025 study of 790 patients found that modern glucocorticoid therapies had reached only 5% of the observed congenital adrenal hyperplasia cohort by 2023. Immediate-release tablets remain important as affordable options for outpatient tapering schedules.
Complete Report Scope:
- By Product Type
- Cortisone Acetate
- Cortisone Sodium Phosphates
- Others
- By Dosage Form
- Oral Tablets
- Injectable Preparations
- Topical Preparations
- Other Dosage Forms
- By Route of Administration
- Oral Route
- Intra-Articular and Local Injection Route
- Intramuscular Route
- Topical Route
- Other Administration Routes
- By Therapeutic Application
- Adrenal Insufficiency and Congenital Adrenal Hyperplasia
- Rheumatoid and Psoriatic Arthritis
- Osteoarthritis, Bursitis and Tendinitis
- Dermatological Disorders
- Respiratory and Allergic Disorders
- Ophthalmic Inflammatory Disorders
- Hematological and Neoplastic Disorders
- Other Therapeutic Application
- By End User
- Hospitals
- Specialty Clinics
- Physician Offices and Primary-Care Practices
- Ambulatory Surgical Centers
- Homecare Settings
- Others
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 41.66% of global revenue in 2025 and was the largest regional contributor to the Cortisone market. High diagnosis rates for arthritis and autoimmune diseases, reimbursement support for injectable procedures and oral corticosteroids, and established specialist networks in the United States drove regional demand. Canada added volume through provincial public drug formularies, while Mexico emerged as the fastest-growing national opportunity due to expanding private clinic capacity, a large working-age population, and rising demand for musculoskeletal injury treatment. Suppliers addressed this demand through clinic-focused distribution and affordable injectable offerings.Asia-Pacific was forecast to grow at a CAGR of 11.65% through 2031, the fastest regional growth rate in the Cortisone market. China remained a major corticosteroid active pharmaceutical ingredient production base, while India combined export-oriented manufacturing with growing domestic demand. Japan, South Korea, Vietnam, Indonesia, and Thailand offered growth potential through aging populations, increasing healthcare access, and improving specialist density.
The Middle East and Africa remained constrained by affordability, although health infrastructure investment in Saudi Arabia and the United Arab Emirates improved access to essential corticosteroid treatment. Suppliers needed to balance cost-competitive offerings, reliable supply, regulatory compliance, product registrations, distribution capacity, and pricing across varied reimbursement systems. These conditions favored lower-cost generic products in some markets and differentiated formulations in others.
List of Companies Covered in this Report:
- Abbvie
- AdvaCare
- Amneal Pharmaceuticals
- ANI Pharmaceuticals
- AstraZeneca
- Bristol-Myers Squibb
- Chartwell RX, LLC
- Cipla
- Dr. Reddy’s Laboratories
- Eurofarma Laboratorios S.A.
- Farmabios S.p.A.
- Hikma Pharmaceuticals
- Merck
- Pfizer
- Pharmascience
- Sandoz Group AG
- Sanofi
- Sun Pharmaceuticals Industries
- Teva Pharmaceutical Industries
- Viatris
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- AdvaCare Pharma
- Amneal Pharmaceuticals, Inc.
- ANI Pharmaceuticals, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Chartwell RX, LLC
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Eurofarma Laboratorios S.A.
- Farmabios S.p.A.
- Hikma Pharmaceuticals PLC
- Merck & Co., Inc.
- Pfizer Inc.
- Pharmascience Inc.
- Sandoz Group AG
- Sanofi
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
